Related references
Note: Only part of the references are listed.Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy
Giuseppe L. Banna et al.
ANTICANCER RESEARCH (2018)
General recommendations paper on the management of older patients with cancer: the SEOM geriatric oncology task force's position statement
R. Girones Sarrio et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
Cesare Gridelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status
C. Bilir et al.
CURRENT ONCOLOGY (2017)
Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current statusand future development
Marina E. Cazzaniga et al.
FUTURE ONCOLOGY (2016)
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
Guido Bocci et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
Andrea Camerini et al.
BMC CANCER (2015)
Metronomics: towards personalized chemotherapy?
Nicolas Andre et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
Evangelos Briasoulis et al.
BMC CANCER (2013)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Elisabeth Quoix et al.
LANCET (2011)
Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer and poor performance status
A. Camerini et al.
ANNALS OF ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials
Rogerio Lilenbaum et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control
HK Weir et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
C Gridelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Share Paper
